

---

---

**Chin-Chung Shu, M.D., Ph.D.**

Internal Medicine, National Taiwan University Hospital and College of Medicine

NO. 7, Chung Shan South Road, Taipei, Taiwan

Phone No.: 0972653087

Fax No.: nil

E-mail: ccshu@ntu.edu.tw

Web: [https://www.mc.ntu.edu.tw/intmed/vcard.action?q\\_type=A10&q\\_itemCode=663](https://www.mc.ntu.edu.tw/intmed/vcard.action?q_type=A10&q_itemCode=663)

---

---

**Education**

- |           |   |
|-----------|---|
| 1996-2003 | M.D., School of Medicine, College of Medicine, Chung Shan Medical University                    |
| 2011-2017 | Ph.D., Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University |

**Research and Professional Positions Held in Chronological Sequence**

- |              |  |
|--------------|--|
| 2018-2021    | Assistant Professor, National Taiwan University College of Medicine  |
| 2016-present | Director of Taiwan Society of Tuberculosis and Lung Diseases   |
| 2017-present | Attending physician, Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital |
| 2020-present | Consultant, Taiwan CDC   |
| 2020-present | Member of Institutional Review Board of Research Ethics Committee, National Taiwan University Hospital                   |
| 2021-present | Associate Professor, National Taiwan University College of Medicine  |

**Research Interests**

We are interested in and devoted us to investigation of mycobacterial pulmonary infection including Tuberculosis and Non-Tuberculous Mycobacterial Lung Disease (NTM-LD).

**For TB diseases**, we conducted many studies in regard to the causes including inhaled corticosteroid (*Medicine*; 2010; Jan;89(1):53-61), and COPD (*PLoS One*. 2012;7(5):e37978), diagnosis (*Eur J Clin Microbiol Infect Dis*. 2012;31(9):2327-33), treatment (*Critical Care* 2012, **16**:R207; *J Infect*. 2012 Mar;64(3):291-8), follow up (*BMC Infectious Diseases*, 2010 Mar 6;10:48.), prognosis (*BMC Infectious Diseases*, 2011 Feb 21;11:46), treatment side effect (CHEST, revised) and pleurisy (*Respirology*, 2015 Jan;20(1):147-54). We reported the burden of TB in cancer and chronic kidney disease. (*Sci Rep*. 2019 15;9(1):11901; *Respir Res*. 2020 12;21(1):51; *IJID* 2021 Dec;113:200-206)

Because **latent TB infection (LTBI)** is the target population in future TB control, we surveyed and published the epidemiology of LTBI in dialysis patients (*PLoS ONE* 2012, 7(8):e42592) and showed dynamic change of LTBI status in dialysis population (*J Infect*. 2013 Dec;67(6):529-35.). The incidence of TB in patients on dialysis has been reported and could be predicted by serial follow up of QuantiFERON-TB Gold In-tube (*Medicine*, 2016 May;95(22):e3813; *Scientific Reports*, 2016 Oct 5;6:34577). We reported apoptosis-associated markers to discriminate active TB from LTBI (*BMC Infect Dis*. 2013 28;13(1):45.). In the downstream study, poor function of Th17 lymphocyte and high Th2 as well as Treg were found in patients with active TB. (*Respiratory research*, 2017 Jun 26;18(1):128). Recently, we reported high prevalence and incidence of LTBI in patient status post kidney transplantation and advise regular screen LTBI in this population (*Clin*

*Infect Dis*, 2020, Aug).

In regard to **NTM-LD**, we initially differentiated NTM lung disease (NTM-LD) from colonization in ICU (*Intensive Care Med*. 2008, 34:2194-201), and investigated NTM with peritonitis (*Clin Microbiol Infect*. 2012 Mar;18(3):246-52), with arthritis (*Ann Rheum Dis*. 2009; 68: 1504-5), and pleuritis (*Int J Tuberc Lung Dis*; 2010; 4:635–641). We also investigated serum markers between NTM-LD and colonization. (*Int J Tuberc Lung* 2011, 15(10):1415–1420) (*Scientific Reports*, 2016 23;6:37266). We had applied a MAC sero-diagnosis kit in Taiwanese MAC-lung disease, and found the sensitivity and specificity were 61% and 91%, respectively (*PLoS One*. 2013 18;8(11):e80473). Based on our team cooperation between VGH and NTUH, we published the predictors and the clinical impact by microbiological persistence in patients with *Mycobacterium avium* complex lung disease (*Clin Infect Dis*, 2017). In addition, program death receptor-1 (PD-1) might play an important role in NTM host immune and clinical prognosis (*Scientific Reports*, 2017; *J Clin Med* 2019). We recently found cavitory lesion and soluble PD-1 could predict NB form of NTM-LD progression (CID, 2022) and *PDCD-1* gene polymorphism leads NTM-LD susceptibility (JID, 2022). For lymphocyte, a TIM3 SNP was found for hyper-expression TIM3 (Front Immunol, 2021 Nov 10;12:738056).

### Major Honors and Awards

2003	The Best Graduate (勤學獎) award, from CSMU
2005	The Best Article in Journal of Internal Medicine of Taiwan, Resident section
2012/2015	The Best Oral Presentation in Annual meeting of TSPCCM
2016	Oral Presentation in 2015 ATS conference
2016	Oral Presentation in Annual meeting of TSPCCM
2016	Young Investigator Award, TSPCCM
2017	Oral Presentation in APSR 2017 conference
2018	The Best Abstract Award in 2018 ATS
2018	Young Investigator Award for Travel Grant in 2018 ERS
2018	Ta-You Wu Memoerial Award (吳大猷先生紀念獎)
2019	Travel Grants in 2019 APCR and KATRD
2019	1953 醫學系黃錦棠醫師紀念獎金
2020	The Best Oral Presentation in Annual meeting of TSPCCM
2021	Oral Presentation in APSR 2021 conference
2021	2021 台大醫院 110 年度教材優良著作獎
2022	Oral Presentation in ATS 2022 conference
2023	12 屆李鎮源院長紀念醫學獎